Assouline, S E
Chang, J
Cheson, B D
Rifkin, R
Hamburg, S
Reyes, R
Hui, A-M
Yu, J
Gupta, N
Di Bacco, A
Shou, Y
Martin, P
Article History
Received: 1 September 2014
Accepted: 2 September 2014
First Online: 17 October 2014
Competing interests
: SE Assouline has received research funding from Roche and Novartis. BD Cheson has served as an advisory board member for Millennium: The Takeda Oncology Company. S Hamburg and R Reyes declare no potential conflicts of interest. J Chang has received research funding from Genentech and Celgene. R Rifkin has served as an advisory board member for Millennium: The Takeda Oncology Company, Onyx, and Celgene, and has received payment for lectures including service on speakers' bureaus for Millennium: The Takeda Oncology Company, Celgene, INCYTE, and Amgen. P Martin has received payment for lectures including service on speakers' bureaus for Millennium: The Takeda Oncology Company.A-M Hui, J Yu, N Gupta, A Di Bacco, and Y Shou are employed by Takeda Pharmaceuticals International Co., Cambridge, MA.